Ockham 'excited' by inhaled heparin trial results

22 February 2016

A British company which develops products for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) has published “exciting” results of a study of their patent protected inhaled heparin.

Ockham Biotech said the Phase IIb study, conducted at Rome’s IRCCS San Raffaele Pisana hospital, investigated the influence of inhaled heparin over 21 days on pulmonary function and exercise capacity amongst 24 moderate to severe COPD patients. Safety parameters were also studied.

Results showed significant increases in lung function as measured by forced expiratory volume in one second (FEV1) and forced vital capacity (FVC), and significantly reduced air trapping as measured by inspiratory capacity (IC), total lung capacity (TLC) and residual volume (RV) against placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK